[go: up one dir, main page]

FR23C1042I1 - PYRROLO[2,3-D]PYRIMIDINYL, PYRROLO[2,3-B]PYRAZINYL AND PYROLLO[2,3-D]PYRIDINYL ACRYLAMIDES - Google Patents

PYRROLO[2,3-D]PYRIMIDINYL, PYRROLO[2,3-B]PYRAZINYL AND PYROLLO[2,3-D]PYRIDINYL ACRYLAMIDES

Info

Publication number
FR23C1042I1
FR23C1042I1 FR23C1042C FR23C1042C FR23C1042I1 FR 23C1042 I1 FR23C1042 I1 FR 23C1042I1 FR 23C1042 C FR23C1042 C FR 23C1042C FR 23C1042 C FR23C1042 C FR 23C1042C FR 23C1042 I1 FR23C1042 I1 FR 23C1042I1
Authority
FR
France
Prior art keywords
pyrrolo
pyrollo
pyrazinyl
pyrimidinyl
acrylamides
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
FR23C1042C
Other languages
French (fr)
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Pfizer Corp Belgium
Pfizer Corp SRL
Original Assignee
Pfizer Corp Belgium
Pfizer Corp SRL
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=52144776&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=FR23C1042(I1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Pfizer Corp Belgium, Pfizer Corp SRL filed Critical Pfizer Corp Belgium
Publication of FR23C1042I1 publication Critical patent/FR23C1042I1/en
Application granted granted Critical
Publication of FR23C1042I2 publication Critical patent/FR23C1042I2/en
Active legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/4375—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a six-membered ring having nitrogen as a ring heteroatom, e.g. quinolizines, naphthyridines, berberine, vincamine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/08—Bronchodilators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/08—Drugs for genital or sexual disorders; Contraceptives for gonadal disorders or for enhancing fertility, e.g. inducers of ovulation or of spermatogenesis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/04—Antipruritics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/14—Drugs for dermatological disorders for baldness or alopecia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/04—Drugs for skeletal disorders for non-specific disorders of the connective tissue
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A61P21/04—Drugs for disorders of the muscular or neuromuscular system for myasthenia gravis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/14—Drugs for disorders of the endocrine system of the thyroid hormones, e.g. T3, T4
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/06—Antianaemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/08—Bridged systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/10—Spiro-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D498/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D498/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Diabetes (AREA)
  • Immunology (AREA)
  • Hematology (AREA)
  • Pulmonology (AREA)
  • Dermatology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Pain & Pain Management (AREA)
  • Psychiatry (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Endocrinology (AREA)
  • Epidemiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Rheumatology (AREA)
  • Psychology (AREA)
  • Obesity (AREA)
  • Cardiology (AREA)
  • Urology & Nephrology (AREA)
  • Reproductive Health (AREA)
  • Hospice & Palliative Care (AREA)
  • Pregnancy & Childbirth (AREA)
  • Vascular Medicine (AREA)
  • Gynecology & Obstetrics (AREA)
FR23C1042C 2013-12-05 2023-11-03 PYRROLO[2,3-D]PYRIMIDINYL, PYRROLO[2,3-B]PYRAZINYL AND PYROLLO[2,3-D]PYRIDINYL ACRYLAMIDES Active FR23C1042I2 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201361912074P 2013-12-05 2013-12-05
PCT/IB2014/066202 WO2015083028A1 (en) 2013-12-05 2014-11-20 Pyrrolo[2,3-d]pyrimidinyl, pyrrolo[2,3-b]pyrazinyl and pyrrolo[2,3-d]pyridinyl acrylamides

Publications (2)

Publication Number Publication Date
FR23C1042I1 true FR23C1042I1 (en) 2023-12-29
FR23C1042I2 FR23C1042I2 (en) 2024-11-15

Family

ID=52144776

Family Applications (1)

Application Number Title Priority Date Filing Date
FR23C1042C Active FR23C1042I2 (en) 2013-12-05 2023-11-03 PYRROLO[2,3-D]PYRIMIDINYL, PYRROLO[2,3-B]PYRAZINYL AND PYROLLO[2,3-D]PYRIDINYL ACRYLAMIDES

Country Status (47)

Country Link
US (3) US9617258B2 (en)
EP (2) EP3077395B1 (en)
JP (2) JP6192839B2 (en)
KR (1) KR101930603B1 (en)
CN (2) CN106061973B (en)
AP (1) AP2016009269A0 (en)
AR (1) AR099363A1 (en)
AU (1) AU2014358792C1 (en)
BR (1) BR112016012262B1 (en)
CA (1) CA2932425C (en)
CL (1) CL2016001216A1 (en)
CR (1) CR20160250A (en)
CU (1) CU24396B1 (en)
CY (3) CY1119778T1 (en)
DK (2) DK3077395T3 (en)
DO (1) DOP2016000124A (en)
EA (1) EA030472B1 (en)
ES (2) ES2654051T3 (en)
FI (1) FIC20230035I1 (en)
FR (1) FR23C1042I2 (en)
GE (1) GEP20186840B (en)
GT (1) GT201600098A (en)
HR (2) HRP20171846T1 (en)
HU (3) HUE054560T2 (en)
IL (1) IL246038B (en)
LT (2) LT3077395T (en)
MA (1) MA39092B1 (en)
MD (1) MD4649C1 (en)
ME (1) ME02883B (en)
MX (1) MX368464B (en)
MY (1) MY187446A (en)
NI (1) NI201600075A (en)
NL (1) NL301245I2 (en)
NO (2) NO3134430T3 (en)
NZ (1) NZ720092A (en)
PE (1) PE20161246A1 (en)
PH (1) PH12016500938B1 (en)
PL (2) PL3318565T3 (en)
PT (2) PT3318565T (en)
RS (2) RS56728B1 (en)
SI (2) SI3318565T1 (en)
SV (1) SV2016005209A (en)
TN (1) TN2016000227A1 (en)
TW (1) TWI548636B (en)
UA (1) UA117040C2 (en)
UY (1) UY35861A (en)
WO (1) WO2015083028A1 (en)

Families Citing this family (86)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN106083887B (en) 2013-09-18 2018-11-20 北京韩美药品有限公司 Inhibit the compound of BTK and/or JAK3 kinase activity
CU24396B1 (en) * 2013-12-05 2019-04-04 Pfizer PIRROLO [2,3-D] PYRIMIDINYL, PIRROLO [2,3-B] PYRAZINYL AND PIRROLO [2,3-D] PIRIDINYL ACRYLIC
WO2016000615A1 (en) * 2014-07-02 2016-01-07 Sunshine Lake Pharma Co., Ltd. Heteroaryl compounds and pharmaceutical applications thereof
JP6563017B2 (en) 2014-08-28 2019-08-21 エースニューロン・ソシエテ・アノニム Glycosidase inhibitor
CN105712998B (en) * 2014-12-05 2019-12-13 上海润诺生物科技有限公司 Azaindole derivatives, preparation method and medical application thereof
EP3247353A4 (en) * 2015-01-23 2018-07-04 Confluence Life Sciences, Inc. Heterocyclic itk inhibitors for treating inflammation and cancer
CN105837574B (en) * 2015-02-02 2018-03-02 四川大学 N (3 piperidyl) aromatic amine derivant and its production and use
ES2928757T3 (en) * 2015-05-01 2022-11-22 Pfizer Pyrrolo[2,3-b]pyrazinyl acrylamides and epoxides thereof as Janus Kinase inhibitors
HUE050842T2 (en) * 2015-05-29 2021-01-28 Wuxi Fortune Pharmaceutical Co Ltd Janus kinase inhibitor
CN106432246B (en) * 2015-08-05 2020-07-07 广东东阳光药业有限公司 Heteroaromatic compounds and their use in medicine
KR101771219B1 (en) * 2015-08-21 2017-09-05 양지화학 주식회사 Janus kinase 1 selective inhibitors and their pharmaceutical use
CA3001542C (en) 2015-11-03 2021-02-16 Theravance Biopharma R&D Ip, Llc Jak kinase inhibitor compounds for treatment of respiratory disease
US9630968B1 (en) 2015-12-23 2017-04-25 Arqule, Inc. Tetrahydropyranyl amino-pyrrolopyrimidinone and methods of use thereof
CA3012560A1 (en) 2016-02-25 2017-08-31 Asceneuron S.A. Glycosidase inhibitors
MX2018010191A (en) 2016-02-25 2019-05-20 Asceneuron S A Glycosidase inhibitors.
US11261183B2 (en) 2016-02-25 2022-03-01 Asceneuron Sa Sulfoximine glycosidase inhibitors
IL260638B2 (en) 2016-02-25 2025-01-01 Asceneuron S A Acid addition salts of piperazine derivatives
WO2018004306A1 (en) * 2016-06-30 2018-01-04 Daewoong Pharmaceutical Co., Ltd. Pyrazolopyrimidine derivatives as kinase inhibitor
SG11201901197PA (en) 2016-08-24 2019-03-28 Arqule Inc Amino-pyrrolopyrimidinone compounds and methods of use thereof
MX2019005319A (en) * 2016-11-23 2019-06-20 Jiangsu Hengrui Medicine Co Preparation method for and intermediate of pyrrolo six-membered heteroaromatic ring derivative.
DK3511333T3 (en) 2016-11-23 2021-08-02 Wuxi Fortune Pharmaceutical Co Ltd CRYSTAL FORM AND SALT FORM OF 7H-PYRROLO [2,3-D] PYRIMIDINE COMPOUND AND METHOD OF MANUFACTURE
WO2018134352A1 (en) 2017-01-20 2018-07-26 Leo Pharma A/S Bicyclic amines as novel jak kinase inhibitors
EP3585790A1 (en) 2017-02-27 2020-01-01 Janssen Pharmaceutica NV [1,2,4]-triazolo [1,5-a]-pyrimidinyl derivatives substituted with piperidine, morpholine or piperazine as oga inhibitors
AU2018231035B2 (en) 2017-03-09 2021-09-09 Theravance Biopharma R&D Ip, Llc Fused imidazo-piperidine JAK inhibitors
CN108794480A (en) * 2017-04-28 2018-11-13 天津药物研究院有限公司 Azolopyrimidines, preparation method and use
AR111495A1 (en) 2017-05-01 2019-07-17 Theravance Biopharma R&D Ip Llc FUSIONED IMIDAZO-PIPERIDINE COMPOUNDS AS JAK INHIBITORS
TW201900170A (en) 2017-05-01 2019-01-01 美商施萬生物製藥研發 Ip有限責任公司 Treatment with JAK inhibitor compounds
WO2018204236A1 (en) 2017-05-01 2018-11-08 Theravance Biopharma R&D Ip, Llc Crystalline forms of a jak inhibitor compound
UA125318C2 (en) 2017-08-01 2022-02-16 Тереванс Байофарма Ар Енд Ді Айпі, Елелсі Pyrazolo and triazolo bicyclic compounds as jak kinase inhibitors
EP3672959A1 (en) 2017-08-24 2020-07-01 Asceneuron SA Linear glycosidase inhibitors
EP3710431A4 (en) 2017-11-03 2021-07-07 Aclaris Therapeutics, Inc. Substituted pyrrolopyrimidine jak inhibitors and methods of making and using the same
CN111315383B (en) * 2017-11-07 2023-09-29 密执安大学评议会 Small molecule inhibitors sharing epitope-calreticulin interactions and methods of use
CN107857778B (en) * 2017-11-21 2020-03-24 江苏乐斯化学有限公司 Process for preparing α -aminonitriles containing phosphono groups
KR102577242B1 (en) * 2017-12-28 2023-09-11 주식회사 대웅제약 Amino-methylpiperidine derivatives as kinase inhibitor
MY194468A (en) * 2017-12-28 2022-11-30 Daewoong Pharmaceutical Co Ltd Oxy-fluoropiperidine derivatives as kinase inhhiitor
KR102577241B1 (en) 2017-12-28 2023-09-11 주식회사 대웅제약 Amino-fluoropiperidine derivatives as kinase inhibitor
WO2019182924A1 (en) * 2018-03-21 2019-09-26 Xibin Liao Jak inhibitors
CN108358797A (en) * 2018-04-20 2018-08-03 南京农业大学 A kind of synthetic method of alkyl glycine
CN108640923A (en) * 2018-07-09 2018-10-12 湖南天地恒制药有限公司 A kind of support method replaces the preparation method of cloth key intermediate
CN112689634B (en) * 2018-08-06 2024-07-16 莫扎制药有限公司 SMAD3 inhibitors
CN112823005B (en) 2018-08-10 2024-08-20 阿克拉瑞斯治疗股份有限公司 Pyrrolopyrimidine ITK inhibitors
WO2020039028A1 (en) 2018-08-22 2020-02-27 Asceneuron S. A. Tetrahydro-benzoazepine glycosidase inhibitors
WO2020039027A1 (en) 2018-08-22 2020-02-27 Asceneuron S. A. Pyrrolidine glycosidase inhibitors
KR20210049849A (en) 2018-08-22 2021-05-06 아셰뉴론 에스아 Succinate and fumarate acid addition salts of piperazine derivatives useful as glycosidase inhibitors
WO2020039029A1 (en) 2018-08-22 2020-02-27 Asceneuron S. A. Spiro compounds as glycosidase inhibitors
MX2021002273A (en) 2018-09-04 2021-05-27 Theravance Biopharma R&D Ip Llc Process for preparing jak inhibitors and intermediates thereof.
BR112021004052A2 (en) 2018-09-04 2021-05-25 Theravance Biopharma R&D Ip, Llc dimethyl-amino azetidine amides as jak inhibitors
EA202190686A1 (en) 2018-09-04 2021-07-23 ТЕРЕВАНС БАЙОФАРМА Ар энд Ди АйПи, ЭлЭлСи 5-7-MEMBER HETEROCYCLIC AMIDES AS JAK INHIBITORS
WO2020067887A1 (en) 2018-09-24 2020-04-02 Erasmus University Medical Center Rotterdam Specific inhibition of janus kinase 3 (jak3) for modulating anti-tumor immune responses
JP6944496B2 (en) * 2018-10-22 2021-10-06 ファイザー・インク Pyrrolo [2,3-d] pyrimidintosilate, its crystal form, and its production method and intermediates.
CN112955451A (en) 2018-10-29 2021-06-11 施万生物制药研发Ip有限责任公司 2-azabicyclohexanes as JAK inhibitors
CA3125039A1 (en) 2019-01-23 2020-07-30 Theravance Biopharma R&D Ip, Llc Imidazo[1,5-a]pyridine, 1,2,4-triazolo[4,3-a]pyridine and imidazo[1,5-a]pyrazine as jak inhibitors
JP7248256B2 (en) * 2019-03-14 2023-03-29 上海華匯拓医薬科技有限公司 JAK Kinase Inhibitors, Preparation Methods Thereof, and Uses Thereof in the Pharmaceutical Field
CN113993585B (en) * 2019-03-27 2024-10-01 英矽智能科技知识产权有限公司 Bicyclic JAK inhibitors and uses thereof
CN113727975A (en) * 2019-05-02 2021-11-30 阿克拉瑞斯治疗股份有限公司 Substituted pyrrolopyridines as JAK inhibitors
WO2020232470A1 (en) 2019-05-13 2020-11-19 Boragen, Inc. Chemical compounds
JOP20210298A1 (en) 2019-05-14 2023-01-30 Provention Bio Inc Methods and compositions for preventing type 1 diabetes
CN110183455B (en) * 2019-06-18 2021-04-20 中国医科大学 Azabicyclo[3.2.1]octan-3-one compounds, preparation method and use thereof
CN112430235B (en) * 2019-08-26 2024-04-05 东莞市东阳光仿制药研发有限公司 PF-06651600 middle Process for the preparation of a body
KR102228668B1 (en) 2019-10-08 2021-03-17 (주)부흥산업사 Manufacturing method of methylpiperidine amino pyrrolo pyrimidine
KR20220101150A (en) 2019-11-14 2022-07-19 화이자 인코포레이티드 1-(((2S,3S,4S)-3-ethyl-4-fluoro-5-oxopyrrolidin-2-yl)methoxy)-7-methoxyisoquinoline-6-carboxamide combination and oral dosage forms
CN112824381B (en) * 2019-11-21 2024-04-26 广东东阳光药业股份有限公司 Preparation method of piperidine amine
MX2022006873A (en) 2019-12-31 2022-08-18 Pfizer R&D Uk Ltd Stable immediate release tablet and capsule formulations of 1-((2s,5r)-5-((7h-pyrrolo[2,3-d]pyrimidin-4-yl)amino)-2-methylp iperidin-1-yl)prop-2-en-1-one.
CN113121539A (en) * 2019-12-31 2021-07-16 江苏艾立康医药科技有限公司 Preparation method of PF06651600
CN113121413B (en) * 2019-12-31 2024-04-09 江苏艾立康医药科技有限公司 Preparation method of key intermediate of JAK3 enzyme inhibitor
CN111138361B (en) * 2020-01-03 2022-05-06 中国医科大学 Substituted phenoxy-2-azabicyclo [3.2.1] octane compounds and preparation method and application thereof
WO2021147953A1 (en) * 2020-01-21 2021-07-29 江苏先声药业有限公司 Pyrimido five-membered ring derivative and application thereof
TW202144343A (en) 2020-03-02 2021-12-01 美商施萬生物製藥研發 Ip有限責任公司 Crystalline hydrate of a jak inhibitor compound
BR112022020020A2 (en) 2020-04-04 2022-11-22 Pfizer METHODS OF TREATMENT OF CORONAVIRUS DISEASE 2019
MX2022015872A (en) 2020-06-11 2023-05-16 Provention Bio Inc Methods and compositions for preventing type 1 diabetes.
CN111620880B (en) * 2020-06-15 2022-06-10 江苏艾立康医药科技有限公司 PF-06651600 DL-tartrate, crystal form and preparation method thereof
CN114835715B (en) * 2020-06-15 2024-04-05 江苏艾立康医药科技有限公司 PF-06651600 maleate and preparation method thereof
WO2022002210A1 (en) * 2020-07-02 2022-01-06 南京明德新药研发有限公司 Pyrimidopyrrolyl deuterated compounds
WO2022012587A1 (en) * 2020-07-14 2022-01-20 苏州晶云药物科技股份有限公司 Malonate crystal form of propenone compound, and preparation method therefor
CN111995623A (en) * 2020-08-18 2020-11-27 上海毕得医药科技有限公司 Synthesis method of 7-bromo-4-chloro-1-methyl-1H-imidazo [4,5-c ] pyridine
KR102473645B1 (en) 2020-08-28 2022-12-05 (주)부흥산업사 Manufacturing method of (2S, 5R)-benzyl 5-(tert-butoxycarbonylamino)-2-methylpiperidine-1-carboxylate
CN113061137B (en) * 2021-04-02 2022-08-02 广西医科大学 Nitrogen-containing heterocyclic derivative or pharmaceutically acceptable salt and application thereof
CN113429427A (en) * 2021-07-05 2021-09-24 湖南南新制药股份有限公司 Heterocyclic compounds, process for their preparation and their use as pharmaceuticals
CN118084939A (en) * 2021-08-25 2024-05-28 杭州禹泓医药科技有限公司 Five-membered heterocycle-fused heterocycloalkyl compound, pharmaceutical composition containing five-membered heterocycle-fused heterocycloalkyl compound and application of five-membered heterocycle-fused heterocycloalkyl compound
WO2023029943A1 (en) * 2021-09-03 2023-03-09 星药科技(北京)有限公司 Aromatic heterocyclic compound, preparation method therefor and use thereof
WO2023151069A1 (en) * 2022-02-14 2023-08-17 湖南南新制药股份有限公司 Pyrrolo[2,3-d]six-membered heteroaromatic ring derivative, and preparation method therefor and pharmaceutical use thereof
WO2024084360A1 (en) 2022-10-18 2024-04-25 Pfizer Inc. Patatin-like phospholipase domain-containing protein 3 (pnpla3) modifiers
WO2024084363A1 (en) 2022-10-18 2024-04-25 Pfizer Inc. Use of patatin-like phospholipase domain-containing protein 3 compounds
WO2024150110A1 (en) 2023-01-11 2024-07-18 Pfizer Inc. Compositions and methods for the treatment and/or prevention of type 1 diabetes
CN116120347B (en) * 2023-01-18 2024-08-23 杭州禹泓医药科技有限公司 Crystal form of aromatic heterocyclic compound, composition, preparation method and application thereof
CN116496280B (en) * 2023-06-25 2023-09-08 北京科翔中升医药科技有限公司 Deuterated acrylamide JAK3 inhibitor medicine and application thereof

Family Cites Families (38)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PA8474101A1 (en) 1998-06-19 2000-09-29 Pfizer Prod Inc PYROLEUM [2,3-D] PIRIMIDINE COMPOUNDS
CA2335492C (en) 1998-06-19 2005-05-17 Pfizer Products Inc. Pyrrolo[2,3-d]pyrimidine compounds
BRPI0016263B8 (en) 1999-12-10 2021-05-25 Pfizer Prod Inc pyrrolo[2,3-d]pyrimidine compounds, pharmaceutical composition comprising them and use of said compounds
KR100516419B1 (en) * 2000-06-26 2005-09-23 화이자 프로덕츠 인크. Pyrrolo[2,3-d]pyrimidine Compounds as Immunosuppressive Agents
US7301023B2 (en) 2001-05-31 2007-11-27 Pfizer Inc. Chiral salt resolution
CN101353321A (en) 2002-11-21 2009-01-28 辉瑞产品公司 3-amino-piperidine derivatives and preparation methods thereof
AR054416A1 (en) * 2004-12-22 2007-06-27 Incyte Corp PIRROLO [2,3-B] PIRIDIN-4-IL-AMINAS AND PIRROLO [2,3-B] PIRIMIDIN-4-IL-AMINAS AS INHIBITORS OF THE JANUS KINASES. PHARMACEUTICAL COMPOSITIONS.
CN102127078A (en) 2005-07-14 2011-07-20 安斯泰来制药株式会社 Heterocyclic janus kinase 3 inhibitors
WO2007012953A2 (en) 2005-07-29 2007-02-01 Pfizer Products Inc. Pyrrolo[2,3-d]pyrimidine derivatives; their intermediates and synthesis
WO2007062459A1 (en) 2005-11-29 2007-06-07 Cytopia Research Pty Ltd Selective kinase inhibitors based on pyridine scaffold
TWI468162B (en) 2005-12-13 2015-01-11 英塞特公司 Heteroaryl substituted pyrrolo[2,3-b]pyridines and pyrrolo[2,3-b]pyrimidines as janus kinase inhibitors
LT2530083T (en) 2006-09-22 2016-09-26 Pharmacyclics Llc Inhibitors of bruton's tyrosine kinase
JO3041B1 (en) 2008-07-25 2016-09-05 Galapagos Nv Novel compounds useful for the treatment of degenerative and inflammatory diseases
ES2378513T3 (en) 2008-08-06 2012-04-13 Pfizer Inc. Compounds 2-heterocyclylamino pyrazines substituted in position 6 as inhibitors of CHK-1
RU2014150660A (en) 2008-09-05 2015-07-20 Селджен Авиломикс Рисерч, Инк. ALGORITHM FOR THE DEVELOPMENT OF IRREVERSIBLE ACTING INHIBITORS
RU2539568C2 (en) 2008-10-31 2015-01-20 Дженентек, Инк. Pyrazolpyrimidine compounds jak inhibitors and methods
MX2011005597A (en) 2008-12-05 2011-06-16 Hoffmann La Roche Pyrrolopyrazinyl urea kinase inhibitors.
JOP20190231A1 (en) 2009-01-15 2017-06-16 Incyte Corp Processes for preparing jak inhibitors and related intermediate compounds
ES2659725T3 (en) * 2009-05-05 2018-03-19 Dana-Farber Cancer Institute, Inc. EGFR inhibitors and disorder treatment procedure
JO3030B1 (en) 2009-06-26 2016-09-05 Galapagos Nv Novel Compound Useful for the Treatment of Degenerative and Inflammatory Diseases
EP2448473A4 (en) 2009-06-30 2014-06-25 Edwards Lifesciences Corp Systems and methods for monitoring and displaying a patient's status
UA110324C2 (en) 2009-07-02 2015-12-25 Genentech Inc Jak inhibitory compounds based on pyrazolo pyrimidine
TW201105674A (en) * 2009-07-08 2011-02-16 Leo Pharma As Novel JAK receptor and protein tyrosine kinase inhibitors and pharmaceutical use thereof
US8486355B2 (en) 2009-08-07 2013-07-16 Metaleach Limited Method for leaching cobalt from oxidised cobalt ores
CA2771822C (en) 2009-09-04 2020-08-11 Daniel A. Erlanson Bruton's tyrosine kinase inhibitors
JP5967827B2 (en) * 2009-12-09 2016-08-10 アジオス ファーマシューティカルズ， インコーポレイテッド Therapeutically active compounds for the treatment of cancer characterized by having an IDH variant
UY33213A (en) 2010-02-18 2011-09-30 Almirall Sa PIRAZOL DERIVATIVES AS JAK INHIBITORS
CA2799904A1 (en) 2010-05-20 2011-11-24 F. Hoffmann-La Roche Ag Pyrrolo [2, 3 - b] pyrazine - 7 - carboxamide derivatives and their use as jak and syk inhibitors
EP2590981B1 (en) * 2010-07-09 2014-09-03 Leo Pharma A/S Novel homopiperazine derivatives as protein tyrosine kinase inhibitors and pharmaceutical use thereof
US8937077B2 (en) * 2010-10-22 2015-01-20 Merck Sharp & Dohme Corp. Bicyclic diamines as janus kinase inhibitors
US8993756B2 (en) * 2011-12-06 2015-03-31 Merck Sharp & Dohme Corp. Pyrrolopyrimidines as janus kinase inhibitors
AU2012357296B2 (en) 2011-12-21 2017-04-13 Jiangsu Hengrui Medicine Co., Ltd. Pyrrole six-membered heteroaryl ring derivative, preparation method therefor, and medicinal uses thereof
AU2013312477B2 (en) * 2012-09-06 2018-05-31 Plexxikon Inc. Compounds and methods for kinase modulation, and indications therefor
EP2920171B1 (en) 2012-11-16 2018-08-29 Merck Sharp & Dohme Corp. Purine inhibitors of human phosphatidylinositol 3-kinase delta
US9676778B2 (en) 2012-11-20 2017-06-13 Principia Biopharma Inc. Substituted pyrrolo[2,3-b]pyrazines as JAK3 inhibitors
CN103896946B (en) * 2012-12-28 2018-04-03 浙江导明医药科技有限公司 For preventing and treating the noval chemical compound of various autoimmune disease
CU24396B1 (en) * 2013-12-05 2019-04-04 Pfizer PIRROLO [2,3-D] PYRIMIDINYL, PIRROLO [2,3-B] PYRAZINYL AND PIRROLO [2,3-D] PIRIDINYL ACRYLIC
US10144737B2 (en) * 2014-05-19 2018-12-04 Jiangsu Hengrui Medicine Co., Ltd. Substituted ethynyl heterobicyclic compounds as tyrosine kinase inhibitors

Also Published As

Publication number Publication date
SI3318565T1 (en) 2021-07-30
KR20160092012A (en) 2016-08-03
NL301245I2 (en) 2023-11-20
KR101930603B1 (en) 2018-12-18
TN2016000227A1 (en) 2017-10-06
ES2654051T3 (en) 2018-02-12
BR112016012262B1 (en) 2021-04-13
IL246038A0 (en) 2016-08-02
DK3077395T3 (en) 2018-01-02
CN107417684A (en) 2017-12-01
MD4649C1 (en) 2020-04-30
GT201600098A (en) 2019-10-17
CU20160077A7 (en) 2017-01-10
CN106061973B (en) 2019-07-09
ME02883B (en) 2018-04-20
EP3077395A1 (en) 2016-10-12
AU2014358792B2 (en) 2017-06-08
CY1124793T1 (en) 2022-11-25
BR112016012262A2 (en) 2020-06-30
NZ720092A (en) 2019-05-31
PE20161246A1 (en) 2016-11-25
JP2016539137A (en) 2016-12-15
NO3134430T3 (en) 2018-08-18
CR20160250A (en) 2016-09-19
GEP20186840B (en) 2018-04-10
UA117040C2 (en) 2018-06-11
CN106061973A (en) 2016-10-26
US20230009153A1 (en) 2023-01-12
RS56728B1 (en) 2018-03-30
US12077533B2 (en) 2024-09-03
DOP2016000124A (en) 2016-10-31
CA2932425C (en) 2018-07-17
DK3318565T3 (en) 2021-05-25
EA201600373A1 (en) 2016-10-31
HUS2300040I1 (en) 2023-12-28
MA39092B1 (en) 2018-09-28
MY187446A (en) 2021-09-22
MA39092A1 (en) 2018-06-29
CU24396B1 (en) 2019-04-04
EP3077395B1 (en) 2017-11-15
CA2932425A1 (en) 2015-06-11
EP3318565A1 (en) 2018-05-09
PT3318565T (en) 2021-05-28
PT3077395T (en) 2018-01-03
AR099363A1 (en) 2016-07-20
TWI548636B (en) 2016-09-11
MX2016007156A (en) 2016-07-21
MX368464B (en) 2019-10-02
CY1119778T1 (en) 2018-06-27
SI3077395T1 (en) 2018-03-30
JP2018008996A (en) 2018-01-18
AU2014358792A1 (en) 2016-06-02
PL3318565T3 (en) 2021-10-04
US9617258B2 (en) 2017-04-11
EP3318565B1 (en) 2021-04-14
PH12016500938A1 (en) 2016-06-27
MD20160058A2 (en) 2016-11-30
HRP20171846T1 (en) 2018-01-12
EA030472B1 (en) 2018-08-31
UY35861A (en) 2015-07-31
RS61897B9 (en) 2021-09-30
CY2024002I2 (en) 2024-09-20
FIC20230035I1 (en) 2023-11-22
NO2024001I1 (en) 2024-01-09
CL2016001216A1 (en) 2017-01-20
AU2014358792C1 (en) 2021-08-26
HRP20210770T1 (en) 2021-06-25
LT3318565T (en) 2021-06-25
PH12016500938B1 (en) 2016-06-27
ES2871524T3 (en) 2021-10-29
RS61897B1 (en) 2021-06-30
CY2024002I1 (en) 2024-09-20
NI201600075A (en) 2016-08-09
MD4649B1 (en) 2019-09-30
IL246038B (en) 2020-10-29
US20170247372A1 (en) 2017-08-31
HUE035264T2 (en) 2018-05-02
US11111242B2 (en) 2021-09-07
JP6192839B2 (en) 2017-09-06
LT3077395T (en) 2018-02-12
HUE054560T2 (en) 2021-09-28
CA2932425E (en) 2015-06-11
AP2016009269A0 (en) 2016-06-30
FR23C1042I2 (en) 2024-11-15
SV2016005209A (en) 2018-04-11
US20150158864A1 (en) 2015-06-11
TW201524977A (en) 2015-07-01
WO2015083028A1 (en) 2015-06-11
PL3077395T3 (en) 2018-04-30

Similar Documents

Publication Publication Date Title
FR23C1042I2 (en) PYRROLO[2,3-D]PYRIMIDINYL, PYRROLO[2,3-B]PYRAZINYL AND PYROLLO[2,3-D]PYRIDINYL ACRYLAMIDES
ZA201507874B (en) 2-aminopyrido[4,3-d]pyrimidin-5-one derivatives and their use as wee-1 inhibitors
IL246311A0 (en) Pyrazolo[1,5-a]pyridine derivatives and methods of their use
SI2914594T1 (en) Amino-substituted imidazo(1,2-a)pyridinecarboxamides and their use
IL243092B (en) Novel triazolo[4,5-d]pyrimidine derivatives
ZA201506747B (en) Imidazo pyridine compounds
IL243525A0 (en) Benzyl-1h-pyrazolo[3,4-b]pyridines and use thereof
EP2970278A4 (en) Pyrrolo[2,3-b]pyridine cdk9 kinase inhibitors
HK1225723A1 (en) Substituted imidazo[1,2-a]pyridinecarboxamides and their use
EP2968332A4 (en) Substituted indol-5-ol derivatives and their therapeutic applications
ZA201507151B (en) Antiviral indolo[2,3-b]quinoxaline
GB201402284D0 (en) Travel cot
TH1601003263A (en) pyrrolo[2,3-D]pyrimidinyl, pyrrolo[2,3-B]pyrazinil and pyrrolo[2,3-D]pyridinyl ac Rylamide
TH1401007032A (en) Synthesis of pyrrolo[2,3-B]pyridine
TH1401006251A (en) 1H-pyrazolo[3,4-B]pyridine and its use in treating disease